Prometheus Biosciences, Inc.
RXDXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001718852
Prometheus Biosciences, Inc. was delisted in 2023; its insiders filed their last Form 4 on Jun 16, 2023; 220 institutions reported holding it in 13F filings for Q1 2023, worth $4.52B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 220
- Q1 2023, +2 vs. previous quarter
- 13F value
- $4.35B
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding RXDX, Q1 2023
No superinvestor reported holding RXDX at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by Prometheus Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2023 (view filing) | Apr 5 | 2 days | Marshall Keith WChief Financial Officer | SSale | −10.0K | $108.42 | −$1.08M | −50.5%9.81K after | |
| Mar 17, 2023 (view filing) | Mar 15 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −25.0K | $116.14 | −$2.90M | −31.2%55.1K after | |
| Mar 8, 2023 (view filing) | Mar 6 | 2 days | Marshall Keith WChief Financial Officer | SSale | −10.0K | $122.13 | −$1.22M | −50.5%9.81K after | |
| Mar 8, 2023 (view filing) | Mar 8 | Same day | Cedars Sinai Intellectual Property Co10% Owner | SSale | −865.0K | $114.59 | −$99.1M | −17.8%4.00M after | |
| Mar 3, 2023 (view filing) | Mar 1-3 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −11.3K | $125.14 | −$1.42M | −17.0%55.1K after | 2 lots |
| Feb 17, 2023 (view filing) | Feb 15 | 2 days | Marshall Keith WChief Financial Officer | SSale | −5.00K | $119.38 | −$596.9K | −33.8%9.81K after | |
| Feb 17, 2023 (view filing) | Feb 15-17 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −63.7K | $120.82 | −$7.69M | −53.6%55.1K after | 3 lots |
| Jan 19, 2023 (view filing) | Jan 17 | 2 days | Marshall Keith WChief Financial Officer | SSale | −5.00K | $119.00 | −$595.0K | −33.8%9.81K after | |
| Jan 19, 2023 (view filing) | Jan 17 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −25.0K | $118.99 | −$2.97M | −31.2%55.1K after |
Top 10 13F holders, Q1 2023
The largest institutional positions in Prometheus Biosciences, Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW Investments, LP | 3,272,104 | $351.2M | 7.31% | −82,199−2.5% | Reduced |
| BlackRock Inc. | 2,799,818 | $300.5M | 0.01% | −7,886−0.3% | Reduced |
| Vanguard Group Inc | 2,716,901 | $291.6M | 0.01% | +860,646+46.4% | Added |
| Boxer Capital, LLC | 1,897,500 | $203.6M | 10.00% | 00.0% | Unchanged |
| 72 Investment Holdings, LLC | 1,848,024 | $198.3M | 93.93% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 1,655,000 | $177.6M | 11.70% | −435,000−20.8% | Reduced |
| Point72 Asset Management, L.P. | 1,465,420 | $157.3M | 0.56% | +199,337+15.7% | Added |
| Fred Alger Management, LLC | 1,331,759 | $142.9M | 0.76% | −27,497−2.0% | Reduced |
| Perceptive Advisors LLC | 1,272,694 | $136.6M | 4.04% | +60,000+4.9% | Added |
| State Street Corp | 1,243,571 | $133.5M | 0.01% | −104,609−7.8% | Reduced |